Key result
Patients with atrial fibrillation and flutter had significantly higher baseline AAG concentrations (122 vs 62 mg/dl, p<0.0005), which reduced the free fraction of quinidine by 32%.
Why the study?
Do alpha1-acid glycoprotein (AAG) concentrations and the free fraction of quinidine change in patients with atrial fibrillation and flutter?
Observational (n=46)
Do alpha1-acid glycoprotein (AAG) concentrations and the free fraction of quinidine change in patients with atrial fibrillation and flutter?
Elevated alpha1-acid glycoprotein concentrations in patients with atrial fibrillation and flutter persist after cardioversion and significantly reduce the free fraction of quinidine, potentially altering its pharmacokinetics.
May reduce quinidine free fraction in AF/flutter; hypothesis-generating for pharmacokinetic studies before dosing changes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
McCollam et al. (1997) conducted an observational in Atrial fibrillation and flutter (n=46). Atrial fibrillation and flutter vs. Matched controls was evaluated on Baseline alpha1-acid glycoprotein (AAG) concentration (mg/dl) (p=<0.0005). Patients with atrial fibrillation and flutter had significantly higher baseline AAG concentrations (122 vs 62 mg/dl, p<0.0005), which reduced the free fraction of quinidine by 32%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: